SlideShare a Scribd company logo
1 of 7
Download to read offline
HEALTH




       mccannhealth.com




LET’S GET CONNECTED
country report              brazil




                                            produced in association with
                                          McCann Health - AMK Healthcare



COUNTRY REPORT

   OVERVIEW                                                EXECUTIVE SUMMARY
   population: 205,716,890*
                                                           •	 Brazil	 had	 a	 healthcare	 expenditure	 of	 US$222.71bn	 in	 2011;	
   Life expectancy: 70 years (men); 77 years (women)          and	 was	 the	 number	 one	 pharmaceutical	 market	 in	 Latin	
                                                              America	and	third	in	America,	with	a	market	value	of	$25.60bn	
   GDp: $2.1trn                                               in	2011
   GDp per capita: $11,127                                 •	 The	medical	devices	market	represented	$4.68bn	in	2011
                                                           •	 Brazil	 was	 the	 largest	 generic	 market,	 at	 $3.25bn	 in	 2010.	
   percentage of GDp spent on health: 9                       Despite	the	government’s	attempts	to	increase	generics	use,	
                                                              patients	and	physicians	still	do	not	trust	its	quality
   GnI per capita: $9,390
                                                           •	 Intellectual	 property	 laws	 remain	 weak,	 with	 the	 consequent	
   capital: Brasilia                                          commercialisation	of	legally	ambiguous	products	on	the	market
                                                           •	 High	enrolment	rates,	lower	labour	costs	and	improving	regulation	
   president: Dilma Rousseff                                  are	creating	an	attractive	centre	of	R&D;	there	are	currently	more	
   Health Minister: Alexandre Padilha                         than	2,000	clinical	trials	being	conducted	in	Brazil
                                                           •	 Corruption	scandals	continue	to	scar	the	political	landscape,	but	
   Language: Portuguese                                       the	government’s	anti-corruption	drive	has	popular	support
                                                           •	 There	is	strong	financial	confidence	linked	to	the	central	bank	
   currency: Real (BRL). Exchange rate: US$1 = R$1.72341
                                                              and	its	response	to	shifting	economic	dynamics	and	also	in	the	
                                                              government’s	commitment	to	fiscal	surpluses.
   (Source: World Bank, 2010-11), *est. July CIA


Pharmaceutical	Market	Europe	June 2012	                                                                       www.pmlive.com/pme     47
country report                    brazil


      Macro operating environment                                                        healthcare policy & expenditure
      Goldman Sachs believes that Brazil could be one of the four leading                In 2010, spending on healthcare reached $178.98bn, with an
      economies in 2050, because of a growth of almost
 140 per cent                     expected compound annual growth rate (CAGR) of 10.04 per
      over the past five years, a huge territory (26 states and one federal              cent by 2015, reaching $355.14bn in value at consumer prices.
      district), vast population, economic stability and political certainty.            Government expenditure on health, which accounted for 46.4 per
      Today, the Brazilian pharmaceutical market is third in America and                 cent of total health expenditure in 2010, is forecast to increase in
      ranks top in Latin America, with a 38 per cent share, compared                     relative terms to 50.27 per cent of total healthcare spending by
      with 21 per cent for Mexico and 16 per cent for Venezuela. Brazil                  2015. In September 2011, the government announced the funding
      also has a high happiness quotient and unites people from around                   of programmes that prevent, diagnose and treat cervical and
      the world through its annual carnival.                                             breast cancer. Nearly $5.6m will be invested to manage both of
        Brazil will stage the 2014 World Cup and 2016 Olympics, both                     these leading causes of death in Brazilian women.
      of which represent a strong growth in infrastructure investment                      In February 2011, Health Minister Alexandre Padilha announced
      ($200bn).                                                                          that medicines for hypertension and diabetes would be supplied
                                                                                         free through a nationwide network of public pharmacies – Farmácia
                                                                                         Popular – and also through private pharmacy chains that subscribe
      Healthcare Services                                                                to the government’s popular pharmacy programme. The popular
      In 1988, Brazil created the Sistema Único de Saúde (SUS), which                    pharmacy programme works with 1.5m patients every month, of
      guarantees healthcare for everybody under the terms its constitu-                  which 700,000 have hypertension and 400,000 have diabetes. In
      tion. In 2007, the Sistema Unificado y Descentralizado de Salud                    Brazil, there are around 32m diagnosed cases of hypertension and
      (SUDS), the main agreement between the government and the                          approximately eight million cases of diabetes. These figures cover
      states to implement the SUS, was created. The health system                        only the diagnosed patients; it is likely that there are actually
      still shows inequalities between rich and poor. Specifically, many                 30-40 per cent more cases. While 80 per cent of patients rely on
      chronic and critical diseases such as diabetes, as well as many                    public healthcare for diagnosis, most pay for treatments from their
      forms of cancer, go untreated due to a lack of preventative care.                  own pocket.
      The SUS has more than 70,000 ambulatory units, 7,000 hospitals                       The Brazilian government finances 90 per cent of medicines
      (private and public) and holds more than 400m consultations                        to treat other conditions, including asthma, allergic rhinitis,
      per year, including 100m with a specialist, seeing mostly chronic                  Parkinson’s disease and osteoporosis. This measure is part of
      patients. The Agência Nacional de Saude Suplementar (the Brazilian                 a campaign to cut extreme poverty, as statistics show that the  
      agency that regulates health plans) estimated in 2008 that 28.6                    poorest of the population spend 12 per cent of their incomes on
      per cent of the population used only the SUS, 61.5 per cent used                   pharmaceuticals. The flagship programme is called PROFARMA,
      a mixture and 8.7 per cent did not use the SUS at all. The private                 led by the Brazilian Development Bank (BNDES), with a budget
      insurance market includes Supplementary Health (45m people)                        of $1.5bn. Its main goal is to create a group of competitive phar-
      and Direct Payment System (DPS) (120m people).                                     maceutical companies to reduce the country’s big pharma trade
        The richest 15 per cent of the population is responsible for over                deficit. PROFARMA represents the future of local pharma companies.
      40 per cent of medicine expenditure. Brazil’s healthcare spending
      represents almost nine per cent of GDP and Swiss business
      network Osec calculates that demand for pharmaceutical products                    Healthcare reform
      grows by 10 per cent a year. Almost 200m people – 20 per cent of                   In January 2009, the World Bank approved a $235m loan to
      the population – have private insurance. In 2010, pharmaceutical                   Brazil’s Health Network Formation and Quality Improvement
      expenditure reached $20.95bn.                                                      Project (QualiSUS). It focuses on improving healthcare services
                                                                                         provided by SUS, delivering systems for the prevention, diagnosis
                                                                                         and treatment of priority health conditions, with an emphasis on
                                                                                         non-communicable diseases. The estimated cost of the project is
      pharmaceutical expenditure
                                                                                         $677m. The continued growth of the Brazilian economy has made
                                                                                         private healthcare (DPS) more affordable.
                                  BRL 36.85bn
        BRL29.10bn                                                   BRL7.75bn
         $16.55bn                                                     $4.41bn            Pricing and reimbursement
                                                                                         The pricing system is faced with two conflicting forces. On
                                                                                         one side, the goverment is trying to keep prices low in a bid
                              21%                                                        to provide unrestricted healthcare, while on the other is an
                                                                                         industry that wants higher prices to increase its profit levels.	
                                                                                            In October 2003, a new agency was created – CMED – charged
                                                                                         with setting retail drug prices and another consumer price index
                                                           79%                           was created: the productivity factor. The agency adopted a refer-
                                                                                         ence pricing system of sorts, which formulates its estimates on an
                                                                                         ‘adequate price coefficient’ based on each drug in a basket of nine
                                                                                         Western countries and the product’s country of origin.
                                                                                           Brazil has a basic reimbursement system, restricted to the public
                                                                                         sector, reflecting the market’s developing nature and traditional
                             Over the                    Prescription                    heritage of private provision. The public healthcare system is
                             counter                                                     limited to medicines on the National List of Essential Drugs
      Sources: Adapted from Brazilian Pharmaceutical Industry Federation (Febrafarma),   (RENAME). Government purchases and reimbursement of so-called
      Group of Executives of the Pharmaceutical Market (Grupemef), IMS Health, BMI
                                                                                         ‘high-priced medicines’ in 2007 were reportedly budgeted at

48	   www.pmlive.com/pme	                                                                                        Pharmaceutical Market Europe June 2012
country report               brazil


$700m. Total state spending and reimbursement of medicines                 Pharmaceutical Market
stood at 12.3 per cent of the total central healthcare budget, with        Brazil is ranked top of the pharmaceutical markets in Latin America
around 70 per cent spent on imported products. Brazil directly             and third in North America, with a market value of $25.60bn in
reimburses medicines used in the Single Health System (SUS) state          2011.  
hospitals for inpatients, as well as for essential and ‘exceptional’       •	 The government has moved to align the drug regulatory
medicines for outpatients in targeted disease groups, including               environment with international standards, including signif-
HIV/AIDS, cancer, diabetes and less common conditions such as                 icant Intellectual Property (IP) reforms
Chagas disease and endometriosis, covering around 400,000                  •	 Higher government spending on public provision is
people.                                                                       improving access to medicines
  In April 2008, a further 225 types of pharmaceutical ingredients         •	 The low-cost generic and biosimilars sectors will play an
were exempted from PIS and COFINS (federal taxes). In July 2010,              ever greater role as the government seeks to find cost-
the Commission for Social Security and Family approved proposals              effective treatments and suppress counterfeit drugs
for new legislation exempting drugs for the treatment of diabetes          •	 Exports will continue to grow as both local and foreign
and hypertension from all federal taxes. Around 51 million people             companies look to expand activity and focus on Brazil as a
suffer from these diseases in Brazil. The Brazilian government and            regional hub
pharmaceutical industry have resumed negotiations over reducing            •	 As happens in other markets, the rise of generics could
ICMS (Brazilian sales tax) rates. According to calculations by the            erode growth of patented medicines.
Brazilian Institute of Tax Planning, ICMS accounts for 17.5 of the
total 35.7 per cent average tax currently added to medicine prices.        Between 2010 and 2015 the Brazilian pharmaceutical market has
                                                                           a predicted CAGR of 7.85 per cent and 10.25 per cent, in local
                                                                           currency and US dollar terms, respectively. The US is the leading
Disease burden                                                             source of imports, accounting for 22.6 per cent in 2010.
Western
Non-communicable chronic diseases were the primary cause of                European countries made up a further 44.2 per cent of imports.
67 per cent of all deaths in the country in 2007. Cardiovascular           Brazil has passed a law to reduce the import of goods – including
diseases, chronic respiratory diseases, cancer and diabetes were           pharmaceuticals – produced outside Mercosur (the common
the main causes, accounting for a total of 705,500 deaths. The             market of Brazil, Argentina, Paraguay and Uruguay). Mercosur
need for anti-depressants is increasing rapidly in emerging                markets will benefit because, even if their prices exceed those
markets, including Brazil, where the prevalence of DSM-IV major            offered by foreign firms by up to 25 per cent, they will be chosen
depressive episodes was 10.4 per cent in a 12-month period.                as providers. To be included in the basic pharma products list, they
  The rapid economic development of Brazil has led to consider-            have to be launched previously in other countries (branded – OTC
able transformations in epidemiological trends. The government             or generics). This basic list is updated every two years, as is the
is increasing its efforts to reduce mortality rates and prevent an         case with the exceptional list, which includes rare, niche and high-
epidemic of chronic non-communicable diseases, mainly through              cost treatments. The products on the basic list are more likely to
investment in education and prevention. This means there are               be generics, while those on the exceptional list  usually come from
considerable growth opportunities in the market for chronic disease        technology transfer deals.
medicines and diagnostics.



                             pharmaceutical market forecast (2007-2021)


   70.00                                                                                                                            2.5

  60.00
                                                                                                                                    2.0
   50.00

                                                                                                                                    1.5
   40.00

   30.00                                                                                                                            1.0

   20.00
                                                                                                                                    0.5
   10.00

    0.00                                                                                                                            0.0
              2007 2008 2009 2010 2011f 2012f 2013f 2014f 2015f 2016f 2017f 2018f 2019f 2020f 2021f

   Pharmaceutical sales ($bn), LHS                  Pharmaceutical sales at CER (US$bn), LHS               Pharmaceutical sales, % of GPD, RHS


Pharmaceutical Market Europe June 2012	                                                                                      www.pmlive.com/pme	   49
country report                  brazil



      MARKETING                                                              RESEARCH & DEVELOPMENT
      A new raft of restrictive rules on advertising has been introduced.    Brazil’s central government remains a primary sponsor of research,
      These affect the communication of safety/product informa-              seeking to increase the country’s drug development and medical
      tion,   requiring that television and radio adverts verbalise such     research capacity, foster its domestic industry and reduce the
      warnings, while text sizes for warnings must be at least 35 per        current trade deficit. In September 2011, the Ministry of Health
      cent of the size of the largest font used in an advert. Television     announced it would invest $881m in the research and develop-
      commercials for medicines can only be broadcast when children          ment (R&D) sector by the end of 2014. The funds are to be allo-
      or adolescents are not likely to be watching.                          cated to ‘neglected diseases’ such as dengue fever, malaria and
        Samples of over-the-counter (OTC) medicines cannot be offered.       tuberculosis.
      In the case of antibiotics or oral contraceptives, samples are           In addition to increasing its R&D commitments, the government
      allowed only if they offer a full treatment period.                    has promised to introduce two new clinical trial programmes. A
        In medical education, the rules state that if a company wishes       law approved in November 2005 provides incentives for innovative
      to offer an unrestricted academic sponsorship, it must submit the      private sector companies, with firms offered a 50 per cent reduc-
      agenda and content to the national health surveillance agency          tion on the Industrialised Products tax on inputs for R&D, as well
      Agência Nacional de Vigilância Sanitária (ANVISA) at least three       as a zero-rate exemption for all costs relating to the protection of
      months before the meeting. Pictures of people ingesting products       intellectual property rights outside Brazil.
      are prohibited and the use of celebrities is heavily restricted.         The biotechnology industry is experiencing faster growth and
                                                                             offering a number of opportunities for international players.
                                                                             Guided by the desire to develop a world-class biotechnology
                                                                             sector, Brazil’s government has pushed through a series of science
      “Brazil’s central government                                           and education reforms designed not only to establish national R&D
      remains a primary sponsor of                                           centres, but also to develop the skilled labour to staff them. Over
                                                                             the course of 2010, eight national laboratories were given public
      research, seeking to enlarge the                                       funding to develop stem cell research projects. Despite the fact
      country’s drug development and                                         that prescriptions for biomedicines are rising in Brazil and that

      medical research capacity”                                             more and more Brazilian companies want to become international
                                                                             drug innovators rather than regional drug producers, a wary public
                                                                             suggests that biotechnology has a long way to go before being
        To apply for OTC status, a drug must demostrate that it has been     broadly accepted. However, Brazil’s imports of medicinal biologics
      available OTC for a minimum of five years in the US or Europe.         rose to $1,589m in 2009.
      The OTC product must exhibit a mandatory red stripe on its               Despite the expansion of multinational drugmakers in the
      packaging. All registered drugs are officially limited to pharmacy     country, 10 out of the largest 21 pharmaceutical companies are
      sale, although some supermarkets sell a limited number of OTCs.        Brazilian, highlighting strong competition from domestic generic
      The  best growth areas in recent years include topical painkillers,    drugmakers. There are some 550 pharmaceutical firms in the
      vitamin supplements, oral hygiene and appetite stimulants.             country, employing around 23,000 staff and meeting the bulk of



        top 15 pharmaceutical and healthcare companies in brazil by revenue (2010)
                                         Headquarters       2008 sales ($m)            2009 sales ($m)               2010 sales ($m)
       Pfizer                                         US                     666.1                       1,932.2                      2,160.7
       Novartis                             Switzerland                      1,115.5                     1,603.7                      1,949.7
       Sanofi                                     France                    1,228.9                      1,583.9                     1,900.0
       Roche                                Switzerland                      734.8                        1,174.2                    1,884.3
       Medley                                      Brazil                    243.1                         918.8                      1,607.7
       AstraZeneca                       UK-Switzerland                      584.4                         899.5                     1,088.9
       EMS Sigma                                   Brazil                    445.0                         727.2                       903.6
       Eurofarma                                   Brazil                    423.6                         696.3                       839.8
       Aché                                        Brazil                    455.8                         683.7                       823.9
       Merck                                     Germany                     332.3                          501.7                       576.9
       Eli Lilly                                      US                     545.2                         819.0                       560.6
       Tortuga                                     Brazil                          -                        391.9                      522.8
       Laboratório Cristália                       Brazil                    254.9                          347.1                      396.6
       Biolab Sanus Farmacéutica                   Brazil                      211.1                        313.2                      380.9
       Bristol-Myers Squibb                           US                     253.1                         365.3                       333.4
      Source: Melhores & Maiores, BMI



50	   www.pmlive.com/pme	                                                                            Pharmaceutical Market Europe June 2012
country report                brazil


demand in unit terms. Of the top 10 firms by sales in 2009, the               on the drugs available to consumers. Since 2002, the government
first four are all foreign multinationals. Pfizer, Novartis and Sanofi        has permitted, but not mandated, generic substitution by pharma-
are clear leaders, followed by Roche, the Brazilian generics firm             cists filing prescriptions under Regulation 135/3. More importantly,
Medley (recently acquired by Sanofi), AstraZeneca (AZ) and Eli Lilly.         doctors are required to use the active pharmaceutical ingredient
  In 2008, the median return on investment percentage figures                 (API) or international non-proprietary name (INN) of the drug when
stood at 9.1 per cent. Companies that achieved double-digit                   writing prescriptions.
percentage returns included AZ (31.4 per cent), Biolab Sanus                    Bioequivalent generic drugs represent a fast-growing sector; by
Farmacêutica (22.6 per cent), Neo Química (14.3 per cent), Bristol-           value, they account for 20 per cent of total prescription drug sales,
Myers Squibb (11.2 per cent) and Roche (10.2 per cent). The large             or 15.5 per cent of total drug expenditure.
concentration of pharmaceutical manufacturing in Brazil is mainly
attributed to strong domestic demand, particularly for manufac-
turers of generics. The market share of the domestic manufac-                 Counterfeiting
turing sector is strong, being estimated at 70 per cent in generics,          Counterfeit drugs coming from Paraguay are still a major problem in
with local firms dominant in terms of volume growth. 
                        Brazil. According to ANVISA, 20 per cent of medicines sold in Brazil
                                                                              are counterfeits. However, that percentage is one of the lowest in
                                                                              Latin America, compared with Argentina, Colombia and Mexico,
Generics                                                                      which have more than 40 per cent, according to the US Food and
Brazil’s generics market is the biggest in Latin America, valued at           Drug Administration (FDA).  
$3.25bn in 2010, and has been the fastest-growing drug sector                   There are a lot of possible causes for the constant presence of
since 2000: almost 25 per cent of medicines sold in Brazil in 2011            fake medicines in Brazil. These include a weak goverment struc-
were generics. Its generic drug market grew by 24.8 per cent in               ture to monitor imports, corruption and a low staffing budget for
real terms during 2010, marking another year of rapid market                  ANVISA.
share gains for the industry.
  While doctors continue to resist prescribing generic medicines (44
per cent of them believe they are more susceptible to counterfeiting          Medical devices
than patented medicines and 46 per cent are dissatisfied with                 ANVISA controls the registration of medical devices, requiring
Brazilian bioequivalence standards), most of the patients – almost            companies to establish a local office or factory, or a local distributor
80 per cent – have confidence in them, which is not a surprise                in order to access the market. ANVISA has its own regulatory stand-
because they already pay for patented products.                               ards; international certification is not accepted without the agency’s
  The increasingly regulated pharmacy retail environment means                quality assurance inspections. Approval of medical devices could
that pharmacists have greater influence over dispensed drugs                  become subject to greater risk-based differentials, if two proposals
and pricing has a greater effect on the consumer’s choice of drug.            from ANVISA are implemented. Under these new measures, a four-
Retail outlets are required to stock around 70 per cent of all generic        tier system could be introduced, similar to the system used in the
products on the national list and to make appropriate information             EU, in which low-risk health products are allowed easier access to
                                                                              market, while higher-risk products require suitable good manufac-
                                                                              turing practice (GMP) certification.
pharmaceutical market by sub-sector                                             Proposed legislation would allow low-risk health products, in
                                                                              classes I and II, more simplified market access by streamlining the
                                                                              approvals process and making product information requirements
                                $bn (2010)                                    more suited to the technical nature of a product. The new regis-
                                                                              tration would be valid for five years. In vitro diagnostic products
                                                                              would be exempt from the simplified procedure. Registration for

                                4,409                                         equipment and materials classified in higher risk groups III and IV
                                                                              would require GMP certification. For in vitro diagnostic products,
                                                                              this would apply to groups II, III and IIIa. Examples of products in
                                                                              these groups are magnetic resonance imaging equipment, ortho-
        3,248                                                                 paedic implants and glucose self-testing devices.
                                                                                The registration process is already relatively swift, taking an
                                                                              average of 10 months. Product registrations are valid for five years
                                                                              and classified according to Law 9.782/99, which divides medical
                                                                              devices into three risk classes (1, 2 and 3). The cost of registration
                                       13,297                                 of a device varies according to the annual revenue of the company
                                                                              and is generally in the range $1,187-$11,877. The private sector
                                                                              accounts for the majority of medical device sales in Brazil (68 per
                                                                              cent), followed by the public sector (21.5 per cent) and exports
                                                                              (8.8 per cent).



                                                                              Healthcare communications
                                                                              As the focus on healthcare continues to grow, so too do the
             Generic                OTC                Patented               fortunes of the main worldwide agencies based in Brazil. With
Source: Brazilian Pharmaceutical Industry Federation (Febrafarma), Group of
                                                                              an investment of nearly $100m, the number of professionals
Executives of the Pharmaceutical Market (Grupemef), IMS Health, BMI           specialising in health and pharma (physicians, engineers, editors,
                                                                              app developers) is rising. There are now more than 140 health-

Pharmaceutical Market Europe June 2012	                                                                                            www.pmlive.com/pme	   51
country report               brazil


      care agencies focusing on this field, about 100 of which are small      for physicians, while e-details are improving engagement.
      agencies.                                                                 Patients and caregivers are adopting more proactive approaches,
        Against a background of tighter regulation, collaboration among       leading to better doctor-patient communications. Health informa-
      pharma and healthcare agencies has increased. There are a lot           tion is becoming ever more specialised and there is an urgent
      of new services, including digital channels, plus close scrutiny of     need to fulfil this unmet requirement in Brazil. The use of digital
      certification procedures for campaigns, medical writing and so          channels in creating increased engagement, either with healthcare
      on. Also, there is an increased collaboration in the digital arena      providers (HCP) in an educational setting or through disease aware-
      because of complex and incomplete government regulations. At            ness campaigns aimed at the public and patients, is a priority for
      the same time, there are more programmes being developed to             pharma in Brazil.
      improve patients’ adherence to drugs, promoting better consumer           Specialists are more technology-focused and have been early
      loyalty, even in mass markets. With niche or high priced drugs,         adopters of iPads and electronic medical records, and the numbers
      such programmes are essential.                                          of primary care providers adopting technology and e-health practice
        Brazilian pharmaceutical companies spend almost $700m annually        are growing quickly. More and more HCPs are going online to find
      promoting their products. The investment in sampling, details,          information about clinical trials, diagnostic pathways and treatment
      journals and gifts is going down, while at the same time investment     algorithms, as well as drugs information.
      in digital, mobile and adherence strategies is increasing. Medical
      education investment is expected to grow, because the agencies
      are changing and looking for more return on investment (ROI).           Outlook
      Physicians say that they need to understand all the key features        Prescription and OTC drug sales performance reflect Brazil’s overall
      of the products, so that they can improve patients’ quality of life     market trends, which result from the lack of reimbursement mech-
      ultimately.                                                             anisms and high reliance on out-of-pocket spending. Nevertheless,
                                                                              the burgeoning middle class will sustain consumer spending in
                                                                              the medium term, and it is likely that the prescription market will
      “If pharma companies want to                                            reach a value of around $29.64bn in 2015, up from $16.55bn in
                                                                              2010, when it represented almost 79 per cent of the total market.
      improve their return on investment,                                       Increasingly, more sophisticated medicines are likely to dominate
      they have to adopt an aggressive                                        the prescription drug market in value terms, along with more widely
                                                                              available bioequivalent generic medicines. In general, alimentary
      medical education approach and new                                      and metabolism products will remain the lead drug categories in the
      communication technologies”                                             medium term, although a sustained increase in purchasing power
                                                                              and access to healthcare would see solid growth in central nervous
                                                                              system, cardiovascular and respiratory medicines.

        Medical education programmes aimed at key opinion
      leaders (KOL) are really expanding the reach of impact, and             “The potential for more expensive
      KOL speaker tours reinforce the main marketing campaigns in
      Brazil. Unlike the situation in the US, direct-to-consumer (DTC)
                                                                              patented products remains high,
      advertising of prescription drugs is illegal, with only dermo-	         given the country’s underdeveloped
      cosmetics, OTC and phytotherapeutic products able to use this
      method.
                                                                              R&D sector and reliance on imports”
        Brazil is experiencing new challenges as well as opportunities for
      increasing profitability. Pharmaceutical companies have to adopt an       The potential for more expensive patented products remains
      aggressive medical education approach and new communication             high, given the country’s underdeveloped R&D sector and its high
      technologies (digital media) alongside their conventional salesforce    reliance on imported 
innovative drugs. Sales of patented drugs
      of medical representatives if they want better ROI.                     could reaching a value of $21bn in 2015. The projected continuation
        As there are likely to be fewer blockbuster drugs in future, multi-   of sales expansions is one of the key reasons that multinational
      channel marketing strategies, using digital media, which is cheaper,    research-based drugmakers continue to invest in Brazil.
      can bring the pharmaceutical companies greater ROI. Brazil has
      almost 76 million people connected to the internet, equivalent to
      37.4 per cent of the population. In addition, doctors’ behaviour is
                                                                              The Authors
                                                                              Written by AMK Healthcare Communications – McCann Health. Contacts:
      changing quickly. Doctors are busier seeing increasing number of
                                                                              JD Puentes (left), President & CEO, AMK Healthcare Communications
      patients, so they have little time to see medical representatives and
                                                                              Latin America and John Cahill, CEO, McCann Health. Emails: jdpuentes@
      they are more inclined to obtain the relevant information online. So
                                                                              amkhealthcare.com and John.Cahill@Mccann.com
      pharmaceutical companies need to build their marketing strategies
      around digital media. KOL platforms, webcasts, online marketing,
      blogs, social media, forums, chat rooms and any other such media
      can be effective means to present the company’s products and
      offers through opinion leaders.
        The digital world cannot be ignored. For example, using a visual
      aid for iPad can increase the contact time of presenting details
      to the target consumer from less than a minute to 3.5 minutes.
      Companies are using much of the technology at their disposal to
                                                                               For comprehensive reports on other countries,
      good effect, developing online detail aids and apps. Increasingly,
                                                                               go to www.pmlive.com/countryreports
      they are creating websites that include password-protected portals

52	   www.pmlive.com/pme	                                                                                Pharmaceutical Market Europe June 2012

More Related Content

What's hot

A year after its publication, compliance with the Constitutional Court’s ruli...
A year after its publication, compliance with the Constitutional Court’s ruli...A year after its publication, compliance with the Constitutional Court’s ruli...
A year after its publication, compliance with the Constitutional Court’s ruli...Comisión Colombiana de Juristas
 
Essential Package of Health Services Country Snapshot: Mozambique
Essential Package of Health Services Country Snapshot: MozambiqueEssential Package of Health Services Country Snapshot: Mozambique
Essential Package of Health Services Country Snapshot: MozambiqueHFG Project
 
Essential Package of Health Services and Health Benefit Plans Mapping Brief
Essential Package of Health Services and Health Benefit Plans Mapping BriefEssential Package of Health Services and Health Benefit Plans Mapping Brief
Essential Package of Health Services and Health Benefit Plans Mapping BriefHFG Project
 
HSH Service 2012-14 (Proposed) Agenda
HSH Service 2012-14 (Proposed) AgendaHSH Service 2012-14 (Proposed) Agenda
HSH Service 2012-14 (Proposed) AgendaMichael Hill
 
Community Care in Catalonia and Spain
Community Care in Catalonia and SpainCommunity Care in Catalonia and Spain
Community Care in Catalonia and SpainJosep Vidal-Alaball
 
Rashtriya Swastiya Bima Yojana - RSBY
Rashtriya Swastiya Bima Yojana - RSBYRashtriya Swastiya Bima Yojana - RSBY
Rashtriya Swastiya Bima Yojana - RSBYChanakya Choudary
 
Sabin SIF country fact sheets VII.2016
Sabin SIF country fact sheets VII.2016Sabin SIF country fact sheets VII.2016
Sabin SIF country fact sheets VII.2016Mike McQuestion
 
Health Expenditure & Financing
Health Expenditure & FinancingHealth Expenditure & Financing
Health Expenditure & FinancingAkhilesh Bhargava
 
Ayushman bharat WHAT AND WHY
Ayushman bharat WHAT AND WHYAyushman bharat WHAT AND WHY
Ayushman bharat WHAT AND WHYSourav Pattanayak
 
Health Trends in the Middle East and North Africa
Health Trends in the Middle East and North AfricaHealth Trends in the Middle East and North Africa
Health Trends in the Middle East and North AfricaHFG Project
 
China+(health+reform)+state+council+plan
China+(health+reform)+state+council+planChina+(health+reform)+state+council+plan
China+(health+reform)+state+council+planelmoria
 
Essential Package of Health Services and Health Benefit Plans Mapping Brief
Essential Package of Health Services and Health Benefit Plans Mapping BriefEssential Package of Health Services and Health Benefit Plans Mapping Brief
Essential Package of Health Services and Health Benefit Plans Mapping BriefHFG Project
 
Senate Recomendation on Healthcare Identifiers Bill 2010
Senate Recomendation on Healthcare Identifiers Bill 2010Senate Recomendation on Healthcare Identifiers Bill 2010
Senate Recomendation on Healthcare Identifiers Bill 2010OrthoSearch
 
CV_ADBformat_AlanFairbank_082016
CV_ADBformat_AlanFairbank_082016CV_ADBformat_AlanFairbank_082016
CV_ADBformat_AlanFairbank_082016Alan Fairbank
 

What's hot (19)

A year after its publication, compliance with the Constitutional Court’s ruli...
A year after its publication, compliance with the Constitutional Court’s ruli...A year after its publication, compliance with the Constitutional Court’s ruli...
A year after its publication, compliance with the Constitutional Court’s ruli...
 
Essential Package of Health Services Country Snapshot: Mozambique
Essential Package of Health Services Country Snapshot: MozambiqueEssential Package of Health Services Country Snapshot: Mozambique
Essential Package of Health Services Country Snapshot: Mozambique
 
Essential Package of Health Services and Health Benefit Plans Mapping Brief
Essential Package of Health Services and Health Benefit Plans Mapping BriefEssential Package of Health Services and Health Benefit Plans Mapping Brief
Essential Package of Health Services and Health Benefit Plans Mapping Brief
 
HSH Service 2012-14 (Proposed) Agenda
HSH Service 2012-14 (Proposed) AgendaHSH Service 2012-14 (Proposed) Agenda
HSH Service 2012-14 (Proposed) Agenda
 
Health Spending on the Elderly in Karnataka
Health Spending on the Elderly in KarnatakaHealth Spending on the Elderly in Karnataka
Health Spending on the Elderly in Karnataka
 
Community Care in Catalonia and Spain
Community Care in Catalonia and SpainCommunity Care in Catalonia and Spain
Community Care in Catalonia and Spain
 
Health advocates propose Pork for Universal Health Care; Hire nurses, doctor...
Health advocates propose Pork for Universal Health Care;  Hire nurses, doctor...Health advocates propose Pork for Universal Health Care;  Hire nurses, doctor...
Health advocates propose Pork for Universal Health Care; Hire nurses, doctor...
 
Rashtriya Swastiya Bima Yojana - RSBY
Rashtriya Swastiya Bima Yojana - RSBYRashtriya Swastiya Bima Yojana - RSBY
Rashtriya Swastiya Bima Yojana - RSBY
 
Divesity in the South
Divesity in the SouthDivesity in the South
Divesity in the South
 
Ayushman Bharat Yojana National Health Protection Scheme
Ayushman Bharat Yojana  National Health Protection Scheme Ayushman Bharat Yojana  National Health Protection Scheme
Ayushman Bharat Yojana National Health Protection Scheme
 
Sabin SIF country fact sheets VII.2016
Sabin SIF country fact sheets VII.2016Sabin SIF country fact sheets VII.2016
Sabin SIF country fact sheets VII.2016
 
Health Expenditure & Financing
Health Expenditure & FinancingHealth Expenditure & Financing
Health Expenditure & Financing
 
Ayushman bharat for a new india
Ayushman bharat for a new indiaAyushman bharat for a new india
Ayushman bharat for a new india
 
Ayushman bharat WHAT AND WHY
Ayushman bharat WHAT AND WHYAyushman bharat WHAT AND WHY
Ayushman bharat WHAT AND WHY
 
Health Trends in the Middle East and North Africa
Health Trends in the Middle East and North AfricaHealth Trends in the Middle East and North Africa
Health Trends in the Middle East and North Africa
 
China+(health+reform)+state+council+plan
China+(health+reform)+state+council+planChina+(health+reform)+state+council+plan
China+(health+reform)+state+council+plan
 
Essential Package of Health Services and Health Benefit Plans Mapping Brief
Essential Package of Health Services and Health Benefit Plans Mapping BriefEssential Package of Health Services and Health Benefit Plans Mapping Brief
Essential Package of Health Services and Health Benefit Plans Mapping Brief
 
Senate Recomendation on Healthcare Identifiers Bill 2010
Senate Recomendation on Healthcare Identifiers Bill 2010Senate Recomendation on Healthcare Identifiers Bill 2010
Senate Recomendation on Healthcare Identifiers Bill 2010
 
CV_ADBformat_AlanFairbank_082016
CV_ADBformat_AlanFairbank_082016CV_ADBformat_AlanFairbank_082016
CV_ADBformat_AlanFairbank_082016
 

Viewers also liked

A Brief Update on Healthcare 3D Printing for the Brazilian Congress
A Brief Update on Healthcare 3D Printing for the Brazilian CongressA Brief Update on Healthcare 3D Printing for the Brazilian Congress
A Brief Update on Healthcare 3D Printing for the Brazilian CongressJenny Chen
 
Brazilian healthcare market 6 13-12
Brazilian healthcare market 6 13-12Brazilian healthcare market 6 13-12
Brazilian healthcare market 6 13-12Mikihaim
 
Utilization of the Social Vulnerability Index for Family Health Teams’ Analys...
Utilization of the Social Vulnerability Index for Family Health Teams’ Analys...Utilization of the Social Vulnerability Index for Family Health Teams’ Analys...
Utilization of the Social Vulnerability Index for Family Health Teams’ Analys...rpesapan
 
2° Parte da aula dia 04/04 Faetec
2° Parte da aula dia 04/04 Faetec2° Parte da aula dia 04/04 Faetec
2° Parte da aula dia 04/04 FaetecLaís Araújo
 
Latest update Brazil Regulations By S. Jaime - Qserve Group (Qserve Conferen...
Latest update Brazil Regulations By S. Jaime - Qserve Group  (Qserve Conferen...Latest update Brazil Regulations By S. Jaime - Qserve Group  (Qserve Conferen...
Latest update Brazil Regulations By S. Jaime - Qserve Group (Qserve Conferen...qserveconference2013
 

Viewers also liked (7)

Should I go to Brazil?
Should I go to Brazil? Should I go to Brazil?
Should I go to Brazil?
 
A Brief Update on Healthcare 3D Printing for the Brazilian Congress
A Brief Update on Healthcare 3D Printing for the Brazilian CongressA Brief Update on Healthcare 3D Printing for the Brazilian Congress
A Brief Update on Healthcare 3D Printing for the Brazilian Congress
 
Brazilian healthcare market 6 13-12
Brazilian healthcare market 6 13-12Brazilian healthcare market 6 13-12
Brazilian healthcare market 6 13-12
 
Utilization of the Social Vulnerability Index for Family Health Teams’ Analys...
Utilization of the Social Vulnerability Index for Family Health Teams’ Analys...Utilization of the Social Vulnerability Index for Family Health Teams’ Analys...
Utilization of the Social Vulnerability Index for Family Health Teams’ Analys...
 
2° Parte da aula dia 04/04 Faetec
2° Parte da aula dia 04/04 Faetec2° Parte da aula dia 04/04 Faetec
2° Parte da aula dia 04/04 Faetec
 
Latest update Brazil Regulations By S. Jaime - Qserve Group (Qserve Conferen...
Latest update Brazil Regulations By S. Jaime - Qserve Group  (Qserve Conferen...Latest update Brazil Regulations By S. Jaime - Qserve Group  (Qserve Conferen...
Latest update Brazil Regulations By S. Jaime - Qserve Group (Qserve Conferen...
 
Brazil
BrazilBrazil
Brazil
 

Similar to Brazil Healthcare Report 2012 v.final

Business Note East Wind No.2 - The Chinese Healthcare Challenge (Dec. 2014)
Business Note East Wind No.2 - The Chinese Healthcare Challenge (Dec. 2014)Business Note East Wind No.2 - The Chinese Healthcare Challenge (Dec. 2014)
Business Note East Wind No.2 - The Chinese Healthcare Challenge (Dec. 2014)Stéphane PHETSINORATH
 
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...iosrphr_editor
 
Brazillian Market Favours Entry of Foreign Groups
Brazillian Market Favours Entry of Foreign GroupsBrazillian Market Favours Entry of Foreign Groups
Brazillian Market Favours Entry of Foreign GroupsAmanda Boddington
 
MRC HIVAN Forum 25 October 2011
MRC HIVAN Forum 25 October 2011MRC HIVAN Forum 25 October 2011
MRC HIVAN Forum 25 October 2011info4africa
 
Loksatta's Roadmap to Universal Healthcare
Loksatta's Roadmap to Universal HealthcareLoksatta's Roadmap to Universal Healthcare
Loksatta's Roadmap to Universal HealthcareVasantha Gullapalli
 
Healthcare in Emerging Countries
Healthcare in Emerging CountriesHealthcare in Emerging Countries
Healthcare in Emerging CountriesKausik Lahiri
 
Future of health - An initial perspective - Devi Shetty
Future of health - An initial perspective - Devi ShettyFuture of health - An initial perspective - Devi Shetty
Future of health - An initial perspective - Devi ShettyFuture Agenda
 
Advancing medical-technology-improves-patient-care
Advancing medical-technology-improves-patient-careAdvancing medical-technology-improves-patient-care
Advancing medical-technology-improves-patient-careMarcEpifanioDechos
 
Medicines outlook through_2016_report
Medicines outlook through_2016_reportMedicines outlook through_2016_report
Medicines outlook through_2016_reportUtai Sukviwatsirikul
 
National Healthy Policy by Dr. Anuj.pptx
National Healthy Policy by  Dr. Anuj.pptxNational Healthy Policy by  Dr. Anuj.pptx
National Healthy Policy by Dr. Anuj.pptxDr. Anuj Singh
 
Finance project
Finance projectFinance project
Finance projectAntaraa
 
Incoherent policies pachanee and wibulpolprasert
Incoherent policies  pachanee and wibulpolprasertIncoherent policies  pachanee and wibulpolprasert
Incoherent policies pachanee and wibulpolprasertNithimar Or
 

Similar to Brazil Healthcare Report 2012 v.final (20)

Business Note East Wind No.2 - The Chinese Healthcare Challenge (Dec. 2014)
Business Note East Wind No.2 - The Chinese Healthcare Challenge (Dec. 2014)Business Note East Wind No.2 - The Chinese Healthcare Challenge (Dec. 2014)
Business Note East Wind No.2 - The Chinese Healthcare Challenge (Dec. 2014)
 
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
 
Global Health 2035 - The Lancet Commissions
Global Health 2035 - The Lancet CommissionsGlobal Health 2035 - The Lancet Commissions
Global Health 2035 - The Lancet Commissions
 
Brazillian Market Favours Entry of Foreign Groups
Brazillian Market Favours Entry of Foreign GroupsBrazillian Market Favours Entry of Foreign Groups
Brazillian Market Favours Entry of Foreign Groups
 
MRC HIVAN Forum 25 October 2011
MRC HIVAN Forum 25 October 2011MRC HIVAN Forum 25 October 2011
MRC HIVAN Forum 25 October 2011
 
2014 05 White Paper
2014 05 White Paper2014 05 White Paper
2014 05 White Paper
 
PROJECT REPORT
PROJECT REPORTPROJECT REPORT
PROJECT REPORT
 
Pacific Alliance: Healthcare sector
Pacific Alliance: Healthcare sectorPacific Alliance: Healthcare sector
Pacific Alliance: Healthcare sector
 
Loksatta's Roadmap to Universal Healthcare
Loksatta's Roadmap to Universal HealthcareLoksatta's Roadmap to Universal Healthcare
Loksatta's Roadmap to Universal Healthcare
 
Healthcare in Emerging Countries
Healthcare in Emerging CountriesHealthcare in Emerging Countries
Healthcare in Emerging Countries
 
DELOITTE: 2017 Global Health Sciences Outlook Report - - John G. Baresky
DELOITTE: 2017 Global Health Sciences Outlook Report - - John G. Baresky DELOITTE: 2017 Global Health Sciences Outlook Report - - John G. Baresky
DELOITTE: 2017 Global Health Sciences Outlook Report - - John G. Baresky
 
Future of health - An initial perspective - Devi Shetty
Future of health - An initial perspective - Devi ShettyFuture of health - An initial perspective - Devi Shetty
Future of health - An initial perspective - Devi Shetty
 
sintesis15novingles.pdf
sintesis15novingles.pdfsintesis15novingles.pdf
sintesis15novingles.pdf
 
Health India
Health IndiaHealth India
Health India
 
Advancing medical-technology-improves-patient-care
Advancing medical-technology-improves-patient-careAdvancing medical-technology-improves-patient-care
Advancing medical-technology-improves-patient-care
 
Pharma china-042013-1
Pharma china-042013-1Pharma china-042013-1
Pharma china-042013-1
 
Medicines outlook through_2016_report
Medicines outlook through_2016_reportMedicines outlook through_2016_report
Medicines outlook through_2016_report
 
National Healthy Policy by Dr. Anuj.pptx
National Healthy Policy by  Dr. Anuj.pptxNational Healthy Policy by  Dr. Anuj.pptx
National Healthy Policy by Dr. Anuj.pptx
 
Finance project
Finance projectFinance project
Finance project
 
Incoherent policies pachanee and wibulpolprasert
Incoherent policies  pachanee and wibulpolprasertIncoherent policies  pachanee and wibulpolprasert
Incoherent policies pachanee and wibulpolprasert
 

Recently uploaded

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 

Recently uploaded (20)

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 

Brazil Healthcare Report 2012 v.final

  • 1. HEALTH mccannhealth.com LET’S GET CONNECTED
  • 2. country report brazil produced in association with McCann Health - AMK Healthcare COUNTRY REPORT OVERVIEW EXECUTIVE SUMMARY population: 205,716,890* • Brazil had a healthcare expenditure of US$222.71bn in 2011; Life expectancy: 70 years (men); 77 years (women) and was the number one pharmaceutical market in Latin America and third in America, with a market value of $25.60bn GDp: $2.1trn in 2011 GDp per capita: $11,127 • The medical devices market represented $4.68bn in 2011 • Brazil was the largest generic market, at $3.25bn in 2010. percentage of GDp spent on health: 9 Despite the government’s attempts to increase generics use, patients and physicians still do not trust its quality GnI per capita: $9,390 • Intellectual property laws remain weak, with the consequent capital: Brasilia commercialisation of legally ambiguous products on the market • High enrolment rates, lower labour costs and improving regulation president: Dilma Rousseff are creating an attractive centre of R&D; there are currently more Health Minister: Alexandre Padilha than 2,000 clinical trials being conducted in Brazil • Corruption scandals continue to scar the political landscape, but Language: Portuguese the government’s anti-corruption drive has popular support • There is strong financial confidence linked to the central bank currency: Real (BRL). Exchange rate: US$1 = R$1.72341 and its response to shifting economic dynamics and also in the government’s commitment to fiscal surpluses. (Source: World Bank, 2010-11), *est. July CIA Pharmaceutical Market Europe June 2012 www.pmlive.com/pme 47
  • 3. country report brazil Macro operating environment healthcare policy & expenditure Goldman Sachs believes that Brazil could be one of the four leading In 2010, spending on healthcare reached $178.98bn, with an economies in 2050, because of a growth of almost
 140 per cent expected compound annual growth rate (CAGR) of 10.04 per over the past five years, a huge territory (26 states and one federal cent by 2015, reaching $355.14bn in value at consumer prices. district), vast population, economic stability and political certainty. Government expenditure on health, which accounted for 46.4 per Today, the Brazilian pharmaceutical market is third in America and cent of total health expenditure in 2010, is forecast to increase in ranks top in Latin America, with a 38 per cent share, compared relative terms to 50.27 per cent of total healthcare spending by with 21 per cent for Mexico and 16 per cent for Venezuela. Brazil 2015. In September 2011, the government announced the funding also has a high happiness quotient and unites people from around of programmes that prevent, diagnose and treat cervical and the world through its annual carnival. breast cancer. Nearly $5.6m will be invested to manage both of Brazil will stage the 2014 World Cup and 2016 Olympics, both these leading causes of death in Brazilian women. of which represent a strong growth in infrastructure investment In February 2011, Health Minister Alexandre Padilha announced ($200bn). that medicines for hypertension and diabetes would be supplied free through a nationwide network of public pharmacies – Farmácia Popular – and also through private pharmacy chains that subscribe Healthcare Services to the government’s popular pharmacy programme. The popular In 1988, Brazil created the Sistema Único de Saúde (SUS), which pharmacy programme works with 1.5m patients every month, of guarantees healthcare for everybody under the terms its constitu- which 700,000 have hypertension and 400,000 have diabetes. In tion. In 2007, the Sistema Unificado y Descentralizado de Salud Brazil, there are around 32m diagnosed cases of hypertension and (SUDS), the main agreement between the government and the approximately eight million cases of diabetes. These figures cover states to implement the SUS, was created. The health system only the diagnosed patients; it is likely that there are actually still shows inequalities between rich and poor. Specifically, many 30-40 per cent more cases. While 80 per cent of patients rely on chronic and critical diseases such as diabetes, as well as many public healthcare for diagnosis, most pay for treatments from their forms of cancer, go untreated due to a lack of preventative care. own pocket. The SUS has more than 70,000 ambulatory units, 7,000 hospitals The Brazilian government finances 90 per cent of medicines (private and public) and holds more than 400m consultations to treat other conditions, including asthma, allergic rhinitis, per year, including 100m with a specialist, seeing mostly chronic Parkinson’s disease and osteoporosis. This measure is part of patients. The Agência Nacional de Saude Suplementar (the Brazilian a campaign to cut extreme poverty, as statistics show that the agency that regulates health plans) estimated in 2008 that 28.6 poorest of the population spend 12 per cent of their incomes on per cent of the population used only the SUS, 61.5 per cent used pharmaceuticals. The flagship programme is called PROFARMA, a mixture and 8.7 per cent did not use the SUS at all. The private led by the Brazilian Development Bank (BNDES), with a budget insurance market includes Supplementary Health (45m people) of $1.5bn. Its main goal is to create a group of competitive phar- and Direct Payment System (DPS) (120m people). maceutical companies to reduce the country’s big pharma trade The richest 15 per cent of the population is responsible for over deficit. PROFARMA represents the future of local pharma companies. 40 per cent of medicine expenditure. Brazil’s healthcare spending represents almost nine per cent of GDP and Swiss business network Osec calculates that demand for pharmaceutical products Healthcare reform grows by 10 per cent a year. Almost 200m people – 20 per cent of In January 2009, the World Bank approved a $235m loan to the population – have private insurance. In 2010, pharmaceutical Brazil’s Health Network Formation and Quality Improvement expenditure reached $20.95bn. Project (QualiSUS). It focuses on improving healthcare services provided by SUS, delivering systems for the prevention, diagnosis and treatment of priority health conditions, with an emphasis on non-communicable diseases. The estimated cost of the project is pharmaceutical expenditure $677m. The continued growth of the Brazilian economy has made private healthcare (DPS) more affordable. BRL 36.85bn BRL29.10bn BRL7.75bn $16.55bn $4.41bn Pricing and reimbursement The pricing system is faced with two conflicting forces. On one side, the goverment is trying to keep prices low in a bid 21% to provide unrestricted healthcare, while on the other is an industry that wants higher prices to increase its profit levels. In October 2003, a new agency was created – CMED – charged with setting retail drug prices and another consumer price index 79% was created: the productivity factor. The agency adopted a refer- ence pricing system of sorts, which formulates its estimates on an ‘adequate price coefficient’ based on each drug in a basket of nine Western countries and the product’s country of origin. Brazil has a basic reimbursement system, restricted to the public sector, reflecting the market’s developing nature and traditional Over the Prescription heritage of private provision. The public healthcare system is counter limited to medicines on the National List of Essential Drugs Sources: Adapted from Brazilian Pharmaceutical Industry Federation (Febrafarma), (RENAME). Government purchases and reimbursement of so-called Group of Executives of the Pharmaceutical Market (Grupemef), IMS Health, BMI ‘high-priced medicines’ in 2007 were reportedly budgeted at 48 www.pmlive.com/pme Pharmaceutical Market Europe June 2012
  • 4. country report brazil $700m. Total state spending and reimbursement of medicines Pharmaceutical Market stood at 12.3 per cent of the total central healthcare budget, with Brazil is ranked top of the pharmaceutical markets in Latin America around 70 per cent spent on imported products. Brazil directly and third in North America, with a market value of $25.60bn in reimburses medicines used in the Single Health System (SUS) state 2011. hospitals for inpatients, as well as for essential and ‘exceptional’ • The government has moved to align the drug regulatory medicines for outpatients in targeted disease groups, including environment with international standards, including signif- HIV/AIDS, cancer, diabetes and less common conditions such as icant Intellectual Property (IP) reforms Chagas disease and endometriosis, covering around 400,000 • Higher government spending on public provision is people. improving access to medicines In April 2008, a further 225 types of pharmaceutical ingredients • The low-cost generic and biosimilars sectors will play an were exempted from PIS and COFINS (federal taxes). In July 2010, ever greater role as the government seeks to find cost- the Commission for Social Security and Family approved proposals effective treatments and suppress counterfeit drugs for new legislation exempting drugs for the treatment of diabetes • Exports will continue to grow as both local and foreign and hypertension from all federal taxes. Around 51 million people companies look to expand activity and focus on Brazil as a suffer from these diseases in Brazil. The Brazilian government and regional hub pharmaceutical industry have resumed negotiations over reducing • As happens in other markets, the rise of generics could ICMS (Brazilian sales tax) rates. According to calculations by the erode growth of patented medicines. Brazilian Institute of Tax Planning, ICMS accounts for 17.5 of the total 35.7 per cent average tax currently added to medicine prices. Between 2010 and 2015 the Brazilian pharmaceutical market has a predicted CAGR of 7.85 per cent and 10.25 per cent, in local currency and US dollar terms, respectively. The US is the leading Disease burden source of imports, accounting for 22.6 per cent in 2010.
Western Non-communicable chronic diseases were the primary cause of European countries made up a further 44.2 per cent of imports. 67 per cent of all deaths in the country in 2007. Cardiovascular Brazil has passed a law to reduce the import of goods – including diseases, chronic respiratory diseases, cancer and diabetes were pharmaceuticals – produced outside Mercosur (the common the main causes, accounting for a total of 705,500 deaths. The market of Brazil, Argentina, Paraguay and Uruguay). Mercosur need for anti-depressants is increasing rapidly in emerging markets will benefit because, even if their prices exceed those markets, including Brazil, where the prevalence of DSM-IV major offered by foreign firms by up to 25 per cent, they will be chosen depressive episodes was 10.4 per cent in a 12-month period. as providers. To be included in the basic pharma products list, they The rapid economic development of Brazil has led to consider- have to be launched previously in other countries (branded – OTC able transformations in epidemiological trends. The government or generics). This basic list is updated every two years, as is the is increasing its efforts to reduce mortality rates and prevent an case with the exceptional list, which includes rare, niche and high- epidemic of chronic non-communicable diseases, mainly through cost treatments. The products on the basic list are more likely to investment in education and prevention. This means there are be generics, while those on the exceptional list usually come from considerable growth opportunities in the market for chronic disease technology transfer deals. medicines and diagnostics. pharmaceutical market forecast (2007-2021) 70.00 2.5 60.00 2.0 50.00 1.5 40.00 30.00 1.0 20.00 0.5 10.00 0.00 0.0 2007 2008 2009 2010 2011f 2012f 2013f 2014f 2015f 2016f 2017f 2018f 2019f 2020f 2021f Pharmaceutical sales ($bn), LHS Pharmaceutical sales at CER (US$bn), LHS Pharmaceutical sales, % of GPD, RHS Pharmaceutical Market Europe June 2012 www.pmlive.com/pme 49
  • 5. country report brazil MARKETING RESEARCH & DEVELOPMENT A new raft of restrictive rules on advertising has been introduced. Brazil’s central government remains a primary sponsor of research, These affect the communication of safety/product informa- seeking to increase the country’s drug development and medical tion, requiring that television and radio adverts verbalise such research capacity, foster its domestic industry and reduce the warnings, while text sizes for warnings must be at least 35 per current trade deficit. In September 2011, the Ministry of Health cent of the size of the largest font used in an advert. Television announced it would invest $881m in the research and develop- commercials for medicines can only be broadcast when children ment (R&D) sector by the end of 2014. The funds are to be allo- or adolescents are not likely to be watching. cated to ‘neglected diseases’ such as dengue fever, malaria and Samples of over-the-counter (OTC) medicines cannot be offered. tuberculosis. In the case of antibiotics or oral contraceptives, samples are In addition to increasing its R&D commitments, the government allowed only if they offer a full treatment period. has promised to introduce two new clinical trial programmes. A In medical education, the rules state that if a company wishes law approved in November 2005 provides incentives for innovative to offer an unrestricted academic sponsorship, it must submit the private sector companies, with firms offered a 50 per cent reduc- agenda and content to the national health surveillance agency tion on the Industrialised Products tax on inputs for R&D, as well Agência Nacional de Vigilância Sanitária (ANVISA) at least three as a zero-rate exemption for all costs relating to the protection of months before the meeting. Pictures of people ingesting products intellectual property rights outside Brazil. are prohibited and the use of celebrities is heavily restricted. The biotechnology industry is experiencing faster growth and offering a number of opportunities for international players. Guided by the desire to develop a world-class biotechnology sector, Brazil’s government has pushed through a series of science “Brazil’s central government and education reforms designed not only to establish national R&D remains a primary sponsor of centres, but also to develop the skilled labour to staff them. Over the course of 2010, eight national laboratories were given public research, seeking to enlarge the funding to develop stem cell research projects. Despite the fact country’s drug development and that prescriptions for biomedicines are rising in Brazil and that medical research capacity” more and more Brazilian companies want to become international drug innovators rather than regional drug producers, a wary public suggests that biotechnology has a long way to go before being To apply for OTC status, a drug must demostrate that it has been broadly accepted. However, Brazil’s imports of medicinal biologics available OTC for a minimum of five years in the US or Europe. rose to $1,589m in 2009. The OTC product must exhibit a mandatory red stripe on its Despite the expansion of multinational drugmakers in the packaging. All registered drugs are officially limited to pharmacy country, 10 out of the largest 21 pharmaceutical companies are sale, although some supermarkets sell a limited number of OTCs. Brazilian, highlighting strong competition from domestic generic The best growth areas in recent years include topical painkillers, drugmakers. There are some 550 pharmaceutical firms in the vitamin supplements, oral hygiene and appetite stimulants. country, employing around 23,000 staff and meeting the bulk of top 15 pharmaceutical and healthcare companies in brazil by revenue (2010) Headquarters 2008 sales ($m) 2009 sales ($m) 2010 sales ($m) Pfizer US 666.1 1,932.2 2,160.7 Novartis Switzerland 1,115.5 1,603.7 1,949.7 Sanofi France 1,228.9 1,583.9 1,900.0 Roche Switzerland 734.8 1,174.2 1,884.3 Medley Brazil 243.1 918.8 1,607.7 AstraZeneca UK-Switzerland 584.4 899.5 1,088.9 EMS Sigma Brazil 445.0 727.2 903.6 Eurofarma Brazil 423.6 696.3 839.8 Aché Brazil 455.8 683.7 823.9 Merck Germany 332.3 501.7 576.9 Eli Lilly US 545.2 819.0 560.6 Tortuga Brazil - 391.9 522.8 Laboratório Cristália Brazil 254.9 347.1 396.6 Biolab Sanus Farmacéutica Brazil 211.1 313.2 380.9 Bristol-Myers Squibb US 253.1 365.3 333.4 Source: Melhores & Maiores, BMI 50 www.pmlive.com/pme Pharmaceutical Market Europe June 2012
  • 6. country report brazil demand in unit terms. Of the top 10 firms by sales in 2009, the on the drugs available to consumers. Since 2002, the government first four are all foreign multinationals. Pfizer, Novartis and Sanofi has permitted, but not mandated, generic substitution by pharma- are clear leaders, followed by Roche, the Brazilian generics firm cists filing prescriptions under Regulation 135/3. More importantly, Medley (recently acquired by Sanofi), AstraZeneca (AZ) and Eli Lilly. doctors are required to use the active pharmaceutical ingredient In 2008, the median return on investment percentage figures (API) or international non-proprietary name (INN) of the drug when stood at 9.1 per cent. Companies that achieved double-digit writing prescriptions. percentage returns included AZ (31.4 per cent), Biolab Sanus Bioequivalent generic drugs represent a fast-growing sector; by Farmacêutica (22.6 per cent), Neo Química (14.3 per cent), Bristol- value, they account for 20 per cent of total prescription drug sales, Myers Squibb (11.2 per cent) and Roche (10.2 per cent). The large or 15.5 per cent of total drug expenditure. concentration of pharmaceutical manufacturing in Brazil is mainly attributed to strong domestic demand, particularly for manufac- turers of generics. The market share of the domestic manufac- Counterfeiting turing sector is strong, being estimated at 70 per cent in generics, Counterfeit drugs coming from Paraguay are still a major problem in with local firms dominant in terms of volume growth. 
 Brazil. According to ANVISA, 20 per cent of medicines sold in Brazil are counterfeits. However, that percentage is one of the lowest in Latin America, compared with Argentina, Colombia and Mexico, Generics which have more than 40 per cent, according to the US Food and Brazil’s generics market is the biggest in Latin America, valued at Drug Administration (FDA). $3.25bn in 2010, and has been the fastest-growing drug sector There are a lot of possible causes for the constant presence of since 2000: almost 25 per cent of medicines sold in Brazil in 2011 fake medicines in Brazil. These include a weak goverment struc- were generics. Its generic drug market grew by 24.8 per cent in ture to monitor imports, corruption and a low staffing budget for real terms during 2010, marking another year of rapid market ANVISA. share gains for the industry. While doctors continue to resist prescribing generic medicines (44 per cent of them believe they are more susceptible to counterfeiting Medical devices than patented medicines and 46 per cent are dissatisfied with ANVISA controls the registration of medical devices, requiring Brazilian bioequivalence standards), most of the patients – almost companies to establish a local office or factory, or a local distributor 80 per cent – have confidence in them, which is not a surprise in order to access the market. ANVISA has its own regulatory stand- because they already pay for patented products. ards; international certification is not accepted without the agency’s The increasingly regulated pharmacy retail environment means quality assurance inspections. Approval of medical devices could that pharmacists have greater influence over dispensed drugs become subject to greater risk-based differentials, if two proposals and pricing has a greater effect on the consumer’s choice of drug. from ANVISA are implemented. Under these new measures, a four- Retail outlets are required to stock around 70 per cent of all generic tier system could be introduced, similar to the system used in the products on the national list and to make appropriate information EU, in which low-risk health products are allowed easier access to market, while higher-risk products require suitable good manufac- turing practice (GMP) certification. pharmaceutical market by sub-sector Proposed legislation would allow low-risk health products, in classes I and II, more simplified market access by streamlining the approvals process and making product information requirements $bn (2010) more suited to the technical nature of a product. The new regis- tration would be valid for five years. In vitro diagnostic products would be exempt from the simplified procedure. Registration for 4,409 equipment and materials classified in higher risk groups III and IV would require GMP certification. For in vitro diagnostic products, this would apply to groups II, III and IIIa. Examples of products in these groups are magnetic resonance imaging equipment, ortho- 3,248 paedic implants and glucose self-testing devices. The registration process is already relatively swift, taking an average of 10 months. Product registrations are valid for five years and classified according to Law 9.782/99, which divides medical devices into three risk classes (1, 2 and 3). The cost of registration 13,297 of a device varies according to the annual revenue of the company and is generally in the range $1,187-$11,877. The private sector accounts for the majority of medical device sales in Brazil (68 per cent), followed by the public sector (21.5 per cent) and exports (8.8 per cent). Healthcare communications As the focus on healthcare continues to grow, so too do the Generic OTC Patented fortunes of the main worldwide agencies based in Brazil. With Source: Brazilian Pharmaceutical Industry Federation (Febrafarma), Group of an investment of nearly $100m, the number of professionals Executives of the Pharmaceutical Market (Grupemef), IMS Health, BMI specialising in health and pharma (physicians, engineers, editors, app developers) is rising. There are now more than 140 health- Pharmaceutical Market Europe June 2012 www.pmlive.com/pme 51
  • 7. country report brazil care agencies focusing on this field, about 100 of which are small for physicians, while e-details are improving engagement. agencies. Patients and caregivers are adopting more proactive approaches, Against a background of tighter regulation, collaboration among leading to better doctor-patient communications. Health informa- pharma and healthcare agencies has increased. There are a lot tion is becoming ever more specialised and there is an urgent of new services, including digital channels, plus close scrutiny of need to fulfil this unmet requirement in Brazil. The use of digital certification procedures for campaigns, medical writing and so channels in creating increased engagement, either with healthcare on. Also, there is an increased collaboration in the digital arena providers (HCP) in an educational setting or through disease aware- because of complex and incomplete government regulations. At ness campaigns aimed at the public and patients, is a priority for the same time, there are more programmes being developed to pharma in Brazil. improve patients’ adherence to drugs, promoting better consumer Specialists are more technology-focused and have been early loyalty, even in mass markets. With niche or high priced drugs, adopters of iPads and electronic medical records, and the numbers such programmes are essential. of primary care providers adopting technology and e-health practice Brazilian pharmaceutical companies spend almost $700m annually are growing quickly. More and more HCPs are going online to find promoting their products. The investment in sampling, details, information about clinical trials, diagnostic pathways and treatment journals and gifts is going down, while at the same time investment algorithms, as well as drugs information. in digital, mobile and adherence strategies is increasing. Medical education investment is expected to grow, because the agencies are changing and looking for more return on investment (ROI). Outlook Physicians say that they need to understand all the key features Prescription and OTC drug sales performance reflect Brazil’s overall of the products, so that they can improve patients’ quality of life market trends, which result from the lack of reimbursement mech- ultimately. anisms and high reliance on out-of-pocket spending. Nevertheless, the burgeoning middle class will sustain consumer spending in the medium term, and it is likely that the prescription market will “If pharma companies want to reach a value of around $29.64bn in 2015, up from $16.55bn in 2010, when it represented almost 79 per cent of the total market. improve their return on investment, Increasingly, more sophisticated medicines are likely to dominate they have to adopt an aggressive the prescription drug market in value terms, along with more widely available bioequivalent generic medicines. In general, alimentary medical education approach and new and metabolism products will remain the lead drug categories in the communication technologies” medium term, although a sustained increase in purchasing power and access to healthcare would see solid growth in central nervous system, cardiovascular and respiratory medicines. Medical education programmes aimed at key opinion leaders (KOL) are really expanding the reach of impact, and “The potential for more expensive KOL speaker tours reinforce the main marketing campaigns in Brazil. Unlike the situation in the US, direct-to-consumer (DTC) patented products remains high, advertising of prescription drugs is illegal, with only dermo- given the country’s underdeveloped cosmetics, OTC and phytotherapeutic products able to use this method. R&D sector and reliance on imports” Brazil is experiencing new challenges as well as opportunities for increasing profitability. Pharmaceutical companies have to adopt an The potential for more expensive patented products remains aggressive medical education approach and new communication high, given the country’s underdeveloped R&D sector and its high technologies (digital media) alongside their conventional salesforce reliance on imported 
innovative drugs. Sales of patented drugs of medical representatives if they want better ROI. could reaching a value of $21bn in 2015. The projected continuation As there are likely to be fewer blockbuster drugs in future, multi- of sales expansions is one of the key reasons that multinational channel marketing strategies, using digital media, which is cheaper, research-based drugmakers continue to invest in Brazil. can bring the pharmaceutical companies greater ROI. Brazil has almost 76 million people connected to the internet, equivalent to 37.4 per cent of the population. In addition, doctors’ behaviour is The Authors Written by AMK Healthcare Communications – McCann Health. Contacts: changing quickly. Doctors are busier seeing increasing number of JD Puentes (left), President & CEO, AMK Healthcare Communications patients, so they have little time to see medical representatives and Latin America and John Cahill, CEO, McCann Health. Emails: jdpuentes@ they are more inclined to obtain the relevant information online. So amkhealthcare.com and John.Cahill@Mccann.com pharmaceutical companies need to build their marketing strategies around digital media. KOL platforms, webcasts, online marketing, blogs, social media, forums, chat rooms and any other such media can be effective means to present the company’s products and offers through opinion leaders. The digital world cannot be ignored. For example, using a visual aid for iPad can increase the contact time of presenting details to the target consumer from less than a minute to 3.5 minutes. Companies are using much of the technology at their disposal to For comprehensive reports on other countries, good effect, developing online detail aids and apps. Increasingly, go to www.pmlive.com/countryreports they are creating websites that include password-protected portals 52 www.pmlive.com/pme Pharmaceutical Market Europe June 2012